David A Katzka
Overview
Explore the profile of David A Katzka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
318
Citations
6025
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pomenti S, Katzka D
Curr Gastroenterol Rep
. 2025 Mar;
27(1):21.
PMID: 40072645
Purpose Of Review: Supragastric belching (SGB), rumination syndrome (RS), and abdominophrenic dyssynergia are often misunderstood and underdiagnosed syndromes. Better understanding of these conditions is needed to increase recognition and guide...
2.
Chehade M, Katzka D, Naeger S, Thomas R, Tilton S
Clin Gastroenterol Hepatol
. 2025 Mar;
PMID: 40049343
No abstract available.
3.
Dellon E, Katzka D, Mukkada V, Collins M, Falk G, Richmond C, et al.
Clin Gastroenterol Hepatol
. 2025 Feb;
PMID: 39954913
Background & Aims: We investigated the long-term safety and efficacy of budesonide oral suspension (BOS) in eosinophilic esophagitis (EoE). Methods: This study (SHP621-303) was a 4-year, phase 3, open-label study...
4.
Kamboj A, Katzka D, Vela M, Yadlapati R, Ravi K
Neurogastroenterol Motil
. 2025 Feb;
:e70001.
PMID: 39928375
No abstract available.
5.
David Y, Shah B, Katzka D, DeCross A
Gastroenterology
. 2025 Jan;
PMID: 39884661
No abstract available.
6.
Dellon E, Muir A, Katzka D, Shah S, Sauer B, Aceves S, et al.
Am J Gastroenterol
. 2025 Jan;
120(1):31-59.
PMID: 39745304
Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease of the esophagus. It is diagnosed in the setting of symptoms of esophageal dysfunction and an eosinophilic predominant infiltrate in the esophagus....
7.
Dellon E, Collins M, Katzka D, Mukkada V, Falk G, Zhang W, et al.
Therap Adv Gastroenterol
. 2024 Dec;
17:17562848241307602.
PMID: 39735351
Background: Relapse after corticosteroid withdrawal in eosinophilic esophagitis is not well understood. Objectives: Budesonide oral suspension (BOS) 2.0 mg twice daily (b.i.d.) was evaluated in two consecutive phase III studies...
8.
9.
Hirano I, Collins M, Katzka D, Mukkada V, Falk G, Terreri B, et al.
Am J Gastroenterol
. 2024 Dec;
PMID: 39631042
Introduction: The effect of esophageal dilation history on efficacy outcomes in patients with eosinophilic esophagitis (EoE) receiving swallowed corticosteroids is not well established. Methods: This post hoc analysis assessed data...
10.
Albaneze N, Cotton C, Anderson C, Katzka D, Dellon E
Aliment Pharmacol Ther
. 2024 Dec;
61(2):363-368.
PMID: 39629856
Background: While inflammation is implicated in the development of numerous cancers, whether eosinophilic oesophagitis (EoE) increases the risk of oesophageal cancer (OCa) remains understudied. Aim: To assess whether adults with...